The demand for and challenges of early detection of diseases is growing rapidly due to technological developments. We aim to quantify the effects of screening for a wide range of diseases to help individuals, clinicians and policymakers make an informed choice about the potential/most optimal implementation of screening and informed (non-) participation.
Screening for diseases is a popular concept. Early detection of disease can considerably improve survival and/or quality of life. However, it can also result in false-positive test results or detection of clinically irrelevant disease, leading to unnecessary interventions. Screening can have a beneficial as well as a harmful impact on health, quality of life, and societal cost. Our research focuses on quantifying these health benefits, unfavourable side-effects, impact on quality of life, and cost consequences of introducing screening programmes, and/or tests for high-risk patients.
Our investigations result in recommendations as to whether or not to introduce screening for specific diseases, and on policy decisions to introduce screening in specific ways, also in clinical care and surveillance. We have made major scientific contributions in the areas of:
1. Designing, running and evaluating large-scale multidisciplinary population-based randomised controlled screening trials to establish the efficacy of screening.
2. Evaluating existing (inter)national screening programmes. We are the national evaluation unit for the breast, cervical and colorectal cancer screening programmes in the Netherlands, and also evaluate programmes worldwide.
3. Guiding public health policies on screening using predictions of favourable and unfavourable effects and the cost of screening, based on micro-simulation modelling (CISNET). The United States guidelines for breast, colorectal and lung cancer screening were (in part) based on modelling by our research section.
Company Details
- Employees
- 10
- Address
- Doctor Molewaterplein 40, Rotterdam,netherlands 3015 Gd,netherlands
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Keywords
- Rotterdam.
- HQ
- Rotterdam, Netherlands
- Competitors
- Hubrecht Institute, Informed, OLVG, IXA - Innovation Exchange Amsterdam, Haaglanden Medisch Centrum (HMC), Nederlandse Vereniging voor Gastro-enterologie (NVGE), RIVM National Institute for Public Health and the Environment, Utrecht Centre for Pharmaceutical Policy and Regulation, Georgian Nutrition Society, Public Sector Network.
Erasmus Mc - Evaluation Of Screening Questions
Erasmus Mc - Evaluation Of Screening's website is https://www.publichealthrotterdam.com/research-line/evaluation-of-screening/
Erasmus Mc - Evaluation Of Screening's LinkedIn profile is https://nl.linkedin.com/company/erasmus-mc-evaluation-of-screening
Erasmus Mc - Evaluation Of Screening has
10 employees.
View email and phone details for 10
employees at Erasmus Mc - Evaluation Of Screening.
Erasmus Mc - Evaluation Of Screening's industry is
Research Services
Erasmus Mc - Evaluation Of Screening's top competitors are
Hubrecht Institute,
Informed,
Olvg,
Ixa - Innovation Exchange Amsterdam,
Haaglanden Medisch Centrum (Hmc),
Nederlandse Vereniging Voor Gastro-Enterologie (Nvge),
Rivm National Institute For Public Health And The Environment,
Utrecht Centre For Pharmaceutical Policy And Regulation,
Georgian Nutrition Society,
Public Sector Network.
Erasmus Mc - Evaluation Of Screening's categories are Research Services
